Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Characteristics of the studies describing the effectiveness and safety of SARS‐CoV‐2 vaccines in inflammatory Bowel Disease (IBD) patients

Article Snippet: Hadi et al,2021 , Multicentre, retrospective cohort , United States , Data from TriNetX research network with 5562 IBD patients who received SARS‐CoV‐2 vaccination until April 30,2021 , Age ≥ 16 years with diagnosis of IBD based on ICD‐9‐CM and ICD‐10‐CM Codes with an IBD‐specific medication , BNT 162b2 Vaccine and mRNA‐1273 vaccine , n/a.

Techniques: Vaccines, Biomarker Discovery, Binding Assay, Infection, Medications, Enzyme-linked Immunosorbent Assay

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Studies describing seroconversion after SARS‐CoV‐2 vaccination in inflammatory Bowel Disease patients

Article Snippet: Hadi et al,2021 , Multicentre, retrospective cohort , United States , Data from TriNetX research network with 5562 IBD patients who received SARS‐CoV‐2 vaccination until April 30,2021 , Age ≥ 16 years with diagnosis of IBD based on ICD‐9‐CM and ICD‐10‐CM Codes with an IBD‐specific medication , BNT 162b2 Vaccine and mRNA‐1273 vaccine , n/a.

Techniques: Medications, Vaccines

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Outcomes of studies describing breakthrough CoV‐19 infection in vaccinated inflammatory Bowel Disease (IBD) patients

Article Snippet: Hadi et al,2021 , Multicentre, retrospective cohort , United States , Data from TriNetX research network with 5562 IBD patients who received SARS‐CoV‐2 vaccination until April 30,2021 , Age ≥ 16 years with diagnosis of IBD based on ICD‐9‐CM and ICD‐10‐CM Codes with an IBD‐specific medication , BNT 162b2 Vaccine and mRNA‐1273 vaccine , n/a.

Techniques: Infection, Comparison, Control

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Characteristics of the studies describing the effectiveness and safety of SARS‐CoV‐2 vaccines in inflammatory Bowel Disease (IBD) patients

Article Snippet: Kappelman et al,2021 , Prospective, observational cohort , United States , Survey‐based study of 317 IBD patients recruited via social media, education and outreach efforts of Crohn’s and Colitis foundation , Age ≥ 16 years with diagnosis of IBD diagnosis with receipt of 1 or more doses of SARS‐CoV‐2 vaccines and followed up to 18 months , BNT 162b2 Vaccine and mRNA‐1273 vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Vaccines, Biomarker Discovery, Binding Assay, Infection, Medications, Enzyme-linked Immunosorbent Assay

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Studies describing seroconversion after SARS‐CoV‐2 vaccination in inflammatory Bowel Disease patients

Article Snippet: Kappelman et al,2021 , Prospective, observational cohort , United States , Survey‐based study of 317 IBD patients recruited via social media, education and outreach efforts of Crohn’s and Colitis foundation , Age ≥ 16 years with diagnosis of IBD diagnosis with receipt of 1 or more doses of SARS‐CoV‐2 vaccines and followed up to 18 months , BNT 162b2 Vaccine and mRNA‐1273 vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Medications, Vaccines

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Outcomes of studies describing breakthrough CoV‐19 infection in vaccinated inflammatory Bowel Disease (IBD) patients

Article Snippet: Kappelman et al,2021 , Prospective, observational cohort , United States , Survey‐based study of 317 IBD patients recruited via social media, education and outreach efforts of Crohn’s and Colitis foundation , Age ≥ 16 years with diagnosis of IBD diagnosis with receipt of 1 or more doses of SARS‐CoV‐2 vaccines and followed up to 18 months , BNT 162b2 Vaccine and mRNA‐1273 vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Infection, Comparison, Control